Overview
Prota Therapeutics is a late clinical-stage Australian biotech company developing novel oral immunotherapies for food allergies, with lead product PRT120 targeting peanut allergy remission. PRT120, a high-dose peanut oral immunotherapy, has shown efficacy in inducing sustained unresponsiveness in Phase 2b trials, enabling patients to eat peanuts freely without ongoing treatment. The company, founded in 2016 and headquartered in Melbourne, holds IP from Murdoch Children’s Research Institute and is preparing for Phase 3 trials.
Frequently asked questions
- What is Prota Therapeutics' lead product and its development stage?
- PRT120 is a proprietary high-dose peanut oral immunotherapy in late clinical-stage development, Phase 3-ready, shown to induce remission in 51% of patients in Phase 2b trials with sustained benefits at 2-year follow-up.
- What clinical outcomes has PRT120 demonstrated?
- PRT120 achieves remission of peanut allergy, allowing free peanut consumption without reactions even after weeks or months off treatment, with significant improvements in health-related quality of life compared to placebo or desensitization.
- Where is Prota Therapeutics based and what is their focus?
- Headquartered in Melbourne, Australia, Prota focuses on oral immunotherapies for food allergies, particularly peanut allergy, originating from technology developed at Murdoch Children’s Research Institute.